Last reviewed · How we verify

Brentuximab vedotin and rifampicin

Millennium Pharmaceuticals, Inc. · Phase 1 active Small molecule

Brentuximab vedotin and rifampicin is a Small molecule drug developed by Millennium Pharmaceuticals, Inc.. It is currently in Phase 1 development. Also known as: SGN-35.

At a glance

Generic nameBrentuximab vedotin and rifampicin
Also known asSGN-35
SponsorMillennium Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Brentuximab vedotin and rifampicin

What is Brentuximab vedotin and rifampicin?

Brentuximab vedotin and rifampicin is a Small molecule drug developed by Millennium Pharmaceuticals, Inc..

Who makes Brentuximab vedotin and rifampicin?

Brentuximab vedotin and rifampicin is developed by Millennium Pharmaceuticals, Inc. (see full Millennium Pharmaceuticals, Inc. pipeline at /company/millennium-pharmaceuticals-inc).

Is Brentuximab vedotin and rifampicin also known as anything else?

Brentuximab vedotin and rifampicin is also known as SGN-35.

What development phase is Brentuximab vedotin and rifampicin in?

Brentuximab vedotin and rifampicin is in Phase 1.

Related